Researchers are testing improved venetoclax-based combinations in AML. Multiple MyeloMATCH trials are comparing venetoclax with azacitidine versus cytarabine-based induction in younger intermediate-risk patients (NCT05554393) and in older FLT3-mutated AML patients with gilteritinib (NCT06317649). A Phase 3 trial (NCT06578247) is evaluating quizartinib, a FLT3 inhibitor, added to chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → in FLT3-ITD-negative AML. A Phase 2 trial (NCT06497062) is testing sonrotoclax, a next-generation BCL-2 inhibitor, combined with chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → in newly diagnosed AML. A Phase 3 trial of nilotinib combined with pegylated interferon alfa-2a in CML (PETALs) showed increased rates of deep molecular response with the combination, at the cost of additional toxicity. In CLL, a Phase 3 trial (NCT04608318) is directly comparing ibrutinib monotherapy, venetoclax plus obinutuzumab, and ibrutinib plus venetoclax as first-line options. A Phase 2 trial (NCT05536349) is evaluating the triplet combination of pirtobrutinib, venetoclax, and obinutuzumab in treatment-naive CLL. In ALL, a Phase 3 study (NCT02003222) is adding blinatumomab to standard chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → for newly diagnosed BCR-ABL-negative B-cell ALL. Novel cellular therapies include CD70-targeted chimeric antigen receptorA type of immunotherapy that genetically engineers a patient's own T cells to recognise and destroy cancer cells.Click for full explanation → natural killer (CAR-NK) cell therapy for AML in Phase 1 (NCT06696846) and neoantigen-specific T cell receptor-transduced peripheral blood lymphocytes in hematologic malignancies (NCT06904066). A case report described zanubrutinib monotherapy achieving early responses in hairy cell leukemia variant, a rare B-cell malignancy with limited relapsed-setting options. Preclinical research identifies CD179a and CD81 as potential leukemia-specific therapeutic targets.
Where the evidence stands
Venetoclax-based regimens in AML and CLL have strong Phase 3 support and have shifted treatment practice, particularly for older patients. BTK inhibitors in CLL are backed by multiple Phase 3 trials. Targeted therapiesDrugs that block specific molecules that cancer cells need to grow.Click for full explanation → for CML have decades of evidence and long-term follow-up data showing durable molecular responses. CAR-T cell therapyA type of immunotherapy that reprograms a patient's own T cells to attack cancer.Click for full explanation → is well-established in relapsed or refractory B-cell ALL and is now being extended to AML and other leukemia subtypes, primarily at Phase 1 and Phase 2 stages. Next-generation inhibitors such as pirtobrutinib and sonrotoclax are at Phase 2 and Phase 3, with results still maturing. Neoantigen-targeted cellular therapies and CAR-NK approaches represent more experimental frontiers in early Phase 1 exploration.
What this means for people affected
Leukemia outcomes vary substantially by type, molecular subtype, and patient fitness. For CML, TKIs have made long-term disease control achievable for many people, with some reaching deep enough responses to attempt treatment discontinuation under careful monitoring. For CLL, newer targeted agents have largely replaced chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → as the standard for many patients, offering more manageable long-term therapy. AML remains harder to treat, particularly in older patients, though venetoclax-based combinations have meaningfully expanded options for those unable to tolerate intensive chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →. The active trial landscape suggests that combination strategies, next-generation targeted agents, and novel cell-based therapies will continue to advance outcomes, especially in high-risk and relapsed settings.
Last updated May 4, 2026
Recent research findings
Understanding evidence levels▼
PreclínicoLab or cell studies — no human data yet.
Estudio en animalesResults in animals only — may not apply to humans.
Ensayo Fase 1First-in-human safety testing in small groups.
Ensayo Fase 2Early effectiveness testing in a larger group.
Ensayo Fase 3Large controlled trial — the strongest trial evidence.
Estudio observacionalPatterns observed in populations — not a controlled trial.
RevisiónSummary analysis of multiple existing studies.
MetaanálisisStatistical pooling of results from multiple studies.
Estudio observacionalPatrones observados en poblaciones a lo largo del tiempo, no es un experimento controlado.Published: May 21, 2026
Switching Cancer Treatments May Increase Healthcare Costs
Researchers studied the costs of switching from a common leukemia treatment to a different one in children and young adults. They found that switching treatments was associated with higher healthcare costs. The study suggests that using a monitoring tool may help reduce unnecessary switches.
Why it matters: This finding could be important for understanding the costs of cancer treatment and for developing strategies to manage those costs.
This was a retrospective study using claims data, which may not be designed for research purposes.
Estudio de laboratorioExperimentos de laboratorio en células o tejidos. Sin datos humanos ni animales.Published: May 21, 2026
Viral Gene Variations Affect Immune Response in Cattle
Researchers studied how genetic variations in a virus that affects cattle affect the way the virus interacts with the host's immune system. They found that these variations can change the way the virus produces certain molecules and how the host responds to it. This suggests that the virus may be able to persist in the host by adapting to its immune system.
Why it matters: This finding may help scientists understand how viruses like this one interact with their hosts and potentially influence their ability to persist.
The study was conducted in a controlled experimental system using HEK293T cells and a BLVΔ-miRNA infectious clone.
Estudio observacionalPatrones observados en poblaciones a lo largo del tiempo, no es un experimento controlado.Published: May 20, 2026
Bowel Cancer Care in People with Intellectual Disability
Researchers studied how people with an intellectual disability experience bowel cancer care. They found that people with an intellectual disability are at higher risk of bowel cancer, especially before age 50, and may experience delays in diagnosis and treatment. They also tend to have poorer outcomes.
Why it matters: This study highlights the need for earlier screening and better care for people with intellectual disabilities who are at higher risk of bowel cancer.
Estudio de laboratorioExperimentos de laboratorio en células o tejidos. Sin datos humanos ni animales.Published: May 20, 2026
ZNF184's Role in Cancer Progression Identified in Leukemia Study
Researchers studied how a protein called ZNF184 affects cancer progression in a type of blood cancer called acute lymphoblastic leukemia. They found that ZNF184 can make it harder for cells to repair DNA damage, which can lead to more aggressive cancer. This could be an important factor in how the disease progresses.
Why it matters: This finding could help researchers develop new treatments for acute lymphoblastic leukemia.
Estudio de laboratorioExperimentos de laboratorio en células o tejidos. Sin datos humanos ni animales.Published: May 19, 2026
New Target for Leukemia Treatment Identified
Researchers found that a protein called ZMIZ1 helps block the development of healthy blood cells in leukemia patients. They discovered that removing this protein from leukemia cells in lab experiments caused the cells to mature and become less aggressive. This could lead to new treatment options for leukemia.
Why it matters: This finding could lead to the development of new treatments for leukemia that help restore healthy blood cell development.
Efficacy
Genetic ablation of ZMIZ1 significantly prolongs survival in murine AML models.
The study was conducted in lab experiments and animal models, and further research is needed to confirm these findings in humans.
Ensayo Fase 2Evalúa la eficacia inicial en un grupo más amplio después de establecer la seguridad en la fase 1.Est. completion: May 31, 2030
Testing a Combination of Medications for Blood Cancers
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying a combination of medications to treat patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. The trial is currently recruiting participants. The goal is to evaluate the safety and effectiveness of this treatment approach.
Why it matters: This trial may help researchers better understand how to treat these blood cancers and improve patient outcomes.
Ensayo Fase 2Evalúa la eficacia inicial en un grupo más amplio después de establecer la seguridad en la fase 1.Est. completion: November 30, 2027
Testing a Combination of Medications for Acute Lymphoblastic Leukemia
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying a combination of medications, including blinatumomab, methotrexate, cytarabine, and ponatinib, to treat patients with a specific type of leukemia. The trial is currently recruiting participants. The goal is to learn more about the safety and effectiveness of this treatment combination.
Why it matters: This trial may help doctors develop a more effective treatment plan for patients with Philadelphia chromosome-positive or BCR-ABL positive acute lymphoblastic leukemia.
Ensayo Fase 1Primer ensayo en humanos. Se centra en la seguridad y dosificación en grupos pequeños.Est. completion: November 29, 2027
Testing Combination Therapy for Relapsed or Refractory Acute Myeloid Leukemia
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying a combination of medications to treat acute myeloid leukemia that has come back or is no longer responding to treatment. The trial is currently recruiting participants. The goal is to see how safe and effective this combination is.
Why it matters: This trial may help researchers understand how to improve treatment options for people with relapsed or refractory acute myeloid leukemia.
PreclínicoEstudios de laboratorio o celulares. Sin datos humanos aún.Est. completion: July 27, 2030
T-cell Lymphoma Registry Study Recruiting Participants
This study is a registry for people with various types of T-cell lymphoma. Participants may be asked to provide blood and nail samples. The study is currently recruiting participants.
Why it matters: This registry aims to collect data on people with T-cell lymphoma to better understand the disease and its progression.
Ensayo Fase 2Evalúa la eficacia inicial en un grupo más amplio después de establecer la seguridad en la fase 1.Est. completion: December 31, 2026
Testing Canakinumab for Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the effectiveness of the medication Canakinumab for patients with certain blood disorders, including myelodysplastic syndromes and chronic myelomonocytic leukemia. The trial is currently recruiting participants. The results of this trial are not yet known.
Why it matters: This trial may help researchers understand if Canakinumab is a useful treatment option for patients with these conditions.
PreclínicoEstudios de laboratorio o celulares. Sin datos humanos aún.Est. completion: June 30, 2027
Testing a Web-Based Tool to Help with Acute Leukemia
Researchers are testing a web-based application to see if it can help reduce inequity in the treatment of acute leukemia. The trial is currently recruiting participants. The results of this study are not yet known.
Why it matters: This trial aims to improve access to care for people with acute leukemia.
Ensayo Fase 1Primer ensayo en humanos. Se centra en la seguridad y dosificación en grupos pequeños.Est. completion: December 1, 2026
Testing a New Combination Treatment for Acute Myeloid Leukemia
Researchers are studying a combination of three medications to treat acute myeloid leukemia. The trial is currently recruiting participants. The goal is to see how well this combination works in people with this type of cancer.
Why it matters: This trial may help doctors find a more effective treatment for acute myeloid leukemia.
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Study of Revumenib in Combination With Intensive ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 MutationA change in DNA sequence that can drive cancer development.Click for full explanation →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
Blinatumomab, Inotuzumab Ozogamicin, and Combination ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 MutationA change in DNA sequence that can drive cancer development.Click for full explanation →
